Sermorelin

What it is

Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that stimulates growth hormone secretion from somatotroph cells in the anterior pituitary^{[1 –2 ]}. It is commonly described chemically as GHRH(1-29)-NH2 or GRF(1-29) amide because it consists of the biologically active N-terminal 29-amino-acid fragment of human GHRH^{[1 ,8 ]}. The 1999 BioDrugs review by Prakash and Goa describes sermorelin as “the shortest synthetic peptide with full biological activity of GHRH”^{[8 ]}.

Mechanism

Sermorelin acts upstream of growth hormone itself. Instead of replacing growth hormone directly, it binds the GHRH receptor and stimulates pituitary growth hormone release when functional somatotroph reserve is present^{[8 –9 ]}. This distinction matters clinically because sermorelin response depends on the hypothalamic–pituitary axis; a patient with pituitary inability to secrete growth hormone may not respond the same way as a patient with hypothalamic GHRH deficiency or age-related reduction in pulsatile secretion^{[8 –9 ]}.

Historical FDA approval

Historically, sermorelin acetate was FDA-approved in two Geref products. Geref Diagnostic, approved under NDA 19-863 on December 28, 1990, was indicated for evaluating the ability of pituitary somatotrophs to secrete growth hormone^{[3 ]}. Geref, approved under NDA 20-443 on September 26, 1997, was indicated for treatment of idiopathic growth hormone deficiency in children with growth failure^{[3 ]}. Both products were later discontinued by the manufacturer and moved to the Discontinued Drug Product List section of the Orange Book^{[3 ]}.

FDA determined in 2013 that the discontinued Geref products were not withdrawn from sale for reasons of safety or effectiveness^{[3 ]}. That determination matters because Geref remains listed in the Orange Book discontinued section and can potentially serve as a reference listed drug for an ANDA if other legal and regulatory requirements are met^{[3 ]}. It does not mean that a currently marketed FDA-approved sermorelin product is available in the United States.

Current access

In contemporary practice, sermorelin is discussed mostly as a compounded prescription peptide rather than an actively marketed FDA-approved drug^{[4 –7 ]}. It is typically administered by injection when used clinically or in research, although older research also studied intranasal formulations that were not suitable for routine pediatric use because of declining absorption, antibody development, and local nasal reactions^{[10 ]}. This page describes regulatory status and research evidence; it does not provide dosing instructions or individualized medical guidance.

Regulatory status

Sermorelin has a mixed regulatory history. It was previously FDA-approved as Geref Diagnostic for evaluation of pituitary growth hormone secretion and as Geref for pediatric idiopathic growth hormone deficiency with growth failure^{[3 ]}. The manufacturer discontinued the products, and FDA later determined that the products were not withdrawn for reasons of safety or effectiveness^{[3 ]}. As of May 5, 2026, no actively marketed FDA-approved branded sermorelin product was identified in the FDA-linked sources reviewed for this draft^{[3 –7 ]}.

Compounding under 503A

Under section 503A, state-licensed pharmacies and physicians may compound using a bulk drug substance if the substance complies with an applicable USP or NF monograph, is a component of an FDA-approved drug product if no applicable monograph exists, or appears on FDA’s 503A bulks list if neither of those routes applies^{[4 ]}. Sermorelin acetate is not listed in the April 22, 2026 FDA 503A Category 1, Category 2, or Category 3 nomination PDF^{[5 ]}. However, sermorelin acetate is a component of previously FDA-approved Geref products that remain listed in the Orange Book discontinued section after FDA found they were not withdrawn for safety or effectiveness reasons^{[3 –4 ]}. A legal review should confirm how that “component of an FDA-approved drug product” pathway applies to a specific compounded sermorelin prescription.

Compounding under 503B

Under section 503B, outsourcing facilities may compound a drug product using a bulk drug substance only if the substance appears on FDA’s 503B bulks list or the compounded drug appears on FDA’s drug shortage list at the time of compounding, distribution, and dispensing^{[6 ]}. FDA’s March 21, 2025 503B nominated-substances category PDF lists “Sermorelin Acetate” in 503B Category 1 and marks it with a double asterisk, which FDA uses to designate bulk drug substances that are components of FDA-approved drugs^{[7 ]}. Category 1 is an interim enforcement-policy category for substances under evaluation; it is not the final 503B bulks list^{[6 –7 ]}. The current 503B bulks list page includes only a small set of substances and does not list sermorelin acetate as a substance for which FDA has made a final clinical-need determination^{[6 ]}.

Sermorelin was not part of FDA’s April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list^{[17 ]}. It was also not among the peptide substances removed from FDA’s 503A Category 2 list in FDA’s April 22, 2026 peptide-related update, which addressed BPC-157, TB-500, MOTS-c, Epitalon, DSIP, Semax, Melanotan II, and others^{[5 ]}. That distinction should not be read as FDA approval of compounded sermorelin; it means sermorelin’s compounding status follows the broader 503A/503B framework and its specific discontinued-drug history^{[3 –7 ]}.

Controlled-substance status

Sermorelin is not listed in the federal controlled-substance schedules in 21 CFR Part 1308, and the historical Geref materials reviewed do not identify it as a controlled substance^{[3 ,18 ]}. International status varies by jurisdiction and is not comprehensively reviewed here. Last regulatory verification: May 5, 2026.

Research summary

The strongest historical research context for sermorelin is diagnosis and treatment of pediatric growth hormone deficiency.

Diagnostic use

In diagnostic use, sermorelin was used as a provocative test to assess pituitary somatotroph capacity to secrete growth hormone after stimulation^{[3 ,8 ]}. The BioDrugs review reports that intravenous sermorelin produced rapid and relatively specific growth hormone responses in children being evaluated for growth hormone deficiency, but it also notes that a normal response to sermorelin cannot exclude growth hormone deficiency due to hypothalamic defects^{[8 ]}. This limitation is clinically important because sermorelin tests pituitary responsiveness to GHRH, not every possible cause of impaired growth hormone secretion^{[8 ]}.

Pediatric therapeutic use

Therapeutic pediatric evidence is older and more limited than modern evidence for recombinant human growth hormone. Prakash and Goa concluded that once-daily subcutaneous sermorelin increased height velocity in some prepubertal children with idiopathic growth hormone deficiency and induced catch-up growth in many treated children, but the review also stated that final adult-height effects had not been determined and that sermorelin had not been directly compared with recommended-dose somatropin^{[8 ]}. In an older comparative clinical literature base, growth responses varied substantially, and some studies suggested that responses to GHRH therapy depended on the child’s capacity to secrete growth hormone after GHRH stimulation^{[9 ,11 ]}.

Several early studies examined GHRH(1-29) or related GHRH fragments in short children or children with low growth hormone secretion. Smith and Brook studied 16 prepubertal children with growth hormone insufficiency treated sequentially with GHRH 1-40 and GHRH 1-29, reporting growth acceleration in some but not all children^{[9 ]}. Tauber and colleagues studied continuous subcutaneous GHRH(1-29)-NH2 infusion in six short children with low 24-hour growth hormone secretion and observed restoration of pulsatile growth hormone secretion in some participants, but the study was very small and short in duration^{[11 ]}. These trials support biological activity and proof of concept, not broad claims about adult performance, anti-aging, or body composition.

Intranasal route — not supportive

Intranasal sermorelin-like GHRH(1-29)-NH2 was also studied, but the findings were not supportive of that route in the formulation tested. Hummeling and colleagues treated eight short prepubertal children with intranasal GHRH(1-29)-NH2 for six months^{[10 ]}. Growth-hormone responses and absorption declined over time in many participants, GHRH antibodies developed in three children, and local nasal symptoms such as sneezing, rhinorrhea, and mucosal burning were reported^{[10 ]}. The authors concluded that intranasal GHRH was not suitable in its tested form for children^{[10 ]}.

Adult and age-related research

Adult and age-related research is much thinner than popular “wellness” marketing suggests. Corpas and colleagues studied GHRH(1-29) twice daily in older men and reported increases in growth hormone and IGF-1 levels, but the study was small and focused on endocrine physiology rather than hard clinical outcomes^{[12 ]}. Vittone and colleagues studied 11 healthy ambulatory older men treated with nightly subcutaneous GHRH for six weeks; treatment increased nocturnal growth hormone release and improved a few strength/endurance measures, but it did not change IGF-1, body composition, glucose, insulin, lipid measures, or muscle histology^{[13 ]}. These findings do not establish sermorelin as a proven anti-aging therapy.

Where the evidence ends

The quality of evidence is mixed and indication-specific. Sermorelin has historical FDA approval and clinical literature for pediatric growth hormone deficiency diagnosis and treatment^{[3 ,8 ]}. It has small physiologic studies in older adults showing that GHRH stimulation can increase growth hormone secretion, but there is no modern, large randomized clinical-trial evidence establishing sermorelin for longevity, athletic performance, fat loss, sleep optimization, or adult wellness use^{[12 –13 ]}. Current public claims about sermorelin often extend beyond the available clinical evidence.

Public discourse

Andrew Huberman, PhD, neuroscientist and host of Huberman Lab, discussed sermorelin in the broader context of prescription peptides and secretagogues that stimulate endocrine pathways rather than replacing the downstream hormone directly^{[14 ]}.

Richard F. Walker, PhD, in a 2006 editorial in Clinical Interventions in Aging, argued from an age-management perspective that sermorelin might be preferable to direct growth hormone replacement in some adult contexts. The article is opinion-oriented and should not be treated as clinical-trial evidence^{[15 ]}.

Robin Riddle, NP-C, a guest on Performance Medicine TV, discussed sermorelin as a popular peptide in a clinic-facing podcast. The episode description is promotional in tone and should be interpreted as public discourse, not independent evidence of efficacy^{[16 ]}.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

Historical clinical literature describes sermorelin as generally well tolerated in the studied pediatric diagnostic and treatment contexts, but the evidence base is older and smaller than for current FDA-approved growth hormone products^{[8 ]}. The BioDrugs review reported transient facial flushing and injection-site pain as the most commonly reported adverse events with intravenous single-dose and repeated once-daily subcutaneous sermorelin^{[8 ]}. The Drugs.com Geref monograph lists facial flushing, headache, nausea, injection-site pain/redness/swelling, paleness, strange taste, vomiting, and allergic reactions as possible adverse effects^{[19 ]}.

Intranasal-specific findings

Intranasal GHRH(1-29)-NH2 produced local tolerability issues in a small pediatric pilot study, including sneezing, rhinorrhea, and mild mucosal burning^{[10 ]}. That same study reported GHRH antibodies in three patients after six weeks, along with declining response over time^{[10 ]}. These findings are specific to the intranasal formulation studied and should not be generalized to every route or product, but they illustrate that peptide formulation, route, and immune response matter^{[10 ]}.

Mechanistic and long-term concerns

Mechanistic concerns relate to stimulation of the growth hormone/IGF-1 axis. Growth hormone and IGF-1 pathways affect growth, metabolism, fluid balance, insulin sensitivity, and cell proliferation biology^{[8 ,13 ]}. The older-adult Vittone study did not find significant adverse effects over six weeks, but it was too small and short to establish long-term safety in adult wellness populations^{[13 ]}. Long-term safety data for compounded sermorelin use in adults are limited.

Sermorelin’s effect depends on pituitary reserve, so it is not equivalent to recombinant growth hormone replacement in patients whose pituitary cannot secrete growth hormone^{[8 ]}. It also should not be assumed to reproduce the effects of modern FDA-approved drugs for adult growth hormone deficiency, HIV-associated lipodystrophy, or other endocrine disorders^{[8 ,13 ]}. The safety and efficacy findings from historical Geref studies may not apply to non-FDA-approved compounded products with different concentration, excipients, storage, sterility controls, or route of administration.

Drug-interaction context

Drug-interaction data are not as well characterized in modern labeling because no current FDA-approved sermorelin product is marketed. In practice, evaluation of the growth hormone axis can be affected by other endocrine therapies, hypothalamic–pituitary disease, glucocorticoid exposure, growth hormone therapy, and diagnostic-test protocols, so interpretation of response testing belongs in a qualified endocrine setting^{[8 ]}.

Available through

Sermorelin is not currently available as an actively marketed FDA-approved branded product in the United States based on sources reviewed for this draft^{[3 ]}. It may be available by prescription through compliant compounding channels, depending on the prescriber, state law, pharmacy status, bulk-substance sourcing, and whether the compounder is operating under 503A or 503B requirements^{[4 –7 ]}.

Telehealth platform partnerships are pending verification. Provider listings will be added only after legal and editorial review confirms that the platform uses licensed clinicians, compliant pharmacies, appropriate prescription practices, and lawful compounding pathways. ProPeptideGuide does not link to or endorse gray-market vendors, research-chemical sites, or non-prescription peptide sellers.